Life science management teams fall victim to recurring mistakes and entrapments. This article discusses avoidable missteps in M&A transactions and their respective remedies.
Published in Life Science Leader, January 2018
Authors: Dr. Oded Ben-Joseph and Thomas Busby
As members of a specialized life sciences investment banking group focused on private equity financing and M&A, we often note that life science management teams fall victim to recurring mistakes and entrapments. Below is a list of avoidable missteps in M&A transactions and their respective remedies.
Appointment of Charles Simmons as Managing Director continues to strengthen Outcome’s capabilities
Read MoreOutcome Capital Life Science Market Pulse August 2024 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?